Using DNA as a drug - bioprocessing and delivery strategies
暂无分享,去创建一个
Ying Han | Michael K. Danquah | Gareth M. Forde | Shan Liu | Jenny Ho | M. Danquah | J. Ho | G. Forde | Shan Liu | Ying Han
[1] S Somavarapu,et al. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. , 2005, Advanced drug delivery reviews.
[2] Olivier Denis,et al. Improved Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine Encoding Ag85 by Protein Boosting , 2001, Infection and Immunity.
[3] Magda Marquet,et al. Process development for the manufacture of plasmid DNA vectors for use in gene therapy , 1996 .
[4] J. Biewenga,et al. The role of nasopharyngeal lymphoid tissue. , 1992, Immunology today.
[5] D. Kaslow,et al. A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[6] D. Riesenberg,et al. High-cell-density cultivation of Escherichia coli. , 1991, Current opinion in biotechnology.
[7] Huanting Wang,et al. Process considerations related to the microencapsulation of plasmid DNA via ultrasonic atomization , 2008, Biotechnology and bioengineering.
[8] M. Marquet,et al. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. , 1996, Human gene therapy.
[9] M. A. Liu,et al. DNA vaccines: a review , 2003, Journal of internal medicine.
[10] Katsuji Okuda,et al. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. , 2006, Vaccine.
[11] H. Blanch,et al. Recombinant Protein Expression in High Cell Density Fed-Batch Cultures of Escherichia Coli , 1992, Bio/Technology.
[12] E Keshavarz-Moore,et al. Effects of growth medium selection on plasmid DNA production and initial processing steps. , 2000, Journal of biotechnology.
[13] G W Luli,et al. Comparison of growth, acetate production, and acetate inhibition of Escherichia coli strains in batch and fed-batch fermentations , 1990, Applied and environmental microbiology.
[14] N. Letvin,et al. Chemical adjuvants for plasmid DNA vaccines. , 2007, Vaccine.
[15] J. Cabral,et al. Anion exchange purification of plasmid DNA using expanded bed adsorption , 2000, Bioseparation.
[16] Grzegorz Węgrzyn,et al. Medium design for plasmid DNA production based on stoichiometric model , 2001 .
[17] Gail Sofer,et al. Handbook of Process Chromatography: A Guide to Optimization, Scale Up, and Validation , 1997 .
[18] J. Rhee,et al. Physiological constraints in increasing biomass concentration ofEscherichiacoli B in fed-batch culture , 1987, Biotechnology Letters.
[19] Eastman,et al. Manufacturing and quality control of plasmid-based gene expression systems. , 1998, Advanced drug delivery reviews.
[20] Fred D. Ledley,et al. Pharmaceutical Approach to Somatic Gene Therapy , 1996, Pharmaceutical Research.
[21] I. Chopra,et al. Effect of short-chain organic acids on macromolecular synthesis in Escherichia coli. , 1990, The Journal of applied bacteriology.
[22] Detlev Riesner,et al. High-performance liquid chromatography of high-molecular-weight nucleic acids on the macroporous ion exchanger, nucleogen , 1984 .
[23] D. Scherman,et al. Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography , 1997, Gene Therapy.
[24] S. Lee,et al. High cell-density culture of Escherichia coli. , 1996, Trends in biotechnology.
[25] D. Zabriskie,et al. Factors influencing productivity of fermentations employing recombinant microorganisms , 1986 .
[26] Keiji Fukuda,et al. A global pandemic influenza vaccine action plan. , 2006, Vaccine.
[27] D L Varley,et al. Production of plasmid DNA for human gene therapy using modified alkaline cell lysis and expanded bed anion exchange chromatography. , 1999, Bioseparation.
[28] O Ohara,et al. Sequence-dependent DNA separation by anion-exchange high-performance liquid chromatography. , 1996, Analytical biochemistry.
[29] Richard C. Willson,et al. Purification of plasmid DNA using selective precipitation by compaction agents , 1999, Nature Biotechnology.
[30] R Schilling,et al. A multivalent HIV-vaccine: development of a plasmid DNA for the expression of HIV envelope glycoproteins with hypervariable V3-loop domains. , 2006, Vaccine.
[31] A Lyddiatt,et al. Biochemical recovery and purification of gene therapy vectors. , 1998, Current opinion in biotechnology.
[32] Lorne A. Babiuk,et al. Approaches to Enhance the Efficacy of DNA Vaccines , 2004, Critical reviews in clinical laboratory sciences.
[33] Kristala Jones Prather,et al. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification , 2003 .
[34] Duarte M. F. Prazeres,et al. Design of flowsheets for the recovery and purification of plasmids for gene therapy and DNA vaccination , 2004 .
[35] C L Cooney,et al. Purification of plasmids by triplex affinity interaction. , 1998, Nucleic acids research.
[36] W F Swain,et al. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. , 2003, Veterinary immunology and immunopathology.
[37] C. Huber,et al. Micropellicular stationary phases for high-performance liquid chromatography of double-stranded DNA. , 1998, Journal of chromatography. A.